Metabolism of atypical antipsychotics: Involvement of cytochrome P450 enzymes and relevance for drug-drug interactions

Current Drug Metabolism

Volumn 9, Issue 5, 2008, Pages 410-418

  Urichuk, Liana ^a,b   Prior, Trevor I ^b   Dursun, Serdar ^a,b   Baker, Glen ^b  

^a UNIVERSITY OF ALBERTA   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Amisulpride; Aripiprazole; Atypical antipsychotics; Clozapine; Olanzapine; Paliperidone; Quetiapine; Risperidone; Ziprasidone

Indexed keywords

ALDEHYDE OXIDASE; AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; CAFFEINE; CARBAMAZEPINE; CIPROFLOXACIN; CLOZAPINE; CLOZAPINE N OXIDE; CYTOCHROME P450; CYTOCHROME P450 2C19; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; ERYTHROMYCIN; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; KETOCONAZOLE; LITHIUM; NORCLOZAPINE; OLANZAPINE; PALIPERIDONE; PAROXETINE; PHENYTOIN; QUETIAPINE; QUINOLONE DERIVATIVE; RISPERIDONE; UNINDEXED DRUG; ZIPRASIDONE;

BINDING AFFINITY; CIGARETTE SMOKING; DEMETHYLATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG OXIDATION; DRUG STRUCTURE; DRUG WITHDRAWAL; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME METABOLISM; FOOD DRUG INTERACTION; HUMAN; LOW DRUG DOSE; MONOTHERAPY; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SEIZURE;

ANIMALS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; HUMANS; ISOENZYMES;

EID: 47749140753     PISSN: 13892002     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920008784746373     Document Type: Review

References (145)

1. Kessler, R.C.; McGonagle, K.A. and Zhao, S. (1994) Arch. Gen. Psychiatry, 51, 8-19.
2. American Psychiatric Association (1997) Am. J. Psychiatry, 154(Suppl), 1-63.
3. Canadian Psychiatric Association (1998) Can. J. Psychiatry, 43(Suppl 2), 25S-40S.
4. Parkinson A. (1996) in Casarett and Doull's Toxicology: The Basic Science of Poisons, (Klaassen, C.D. Ed.), McGraw-Hill, New York, pp. 113-186.
5. Coutts, R.T.; Fang, J.; Bourin, M. and Baker, G.B. (1999) in Neuromethods: Cell Neurobiology Techniques, (Boulton, A.A.; Baker, G.B. and Bateson, A.N. Eds.), Humana Press, Totowa, NJ, pp. 255-286.
6. Ring, B.J. and Wrighton, S.A. (2000) Metabolic Drug Interactions, Lippincott, Williams & Wilkins; Baltimore, MD, pp. 29-39.
7. Raggi, M.A.; Mandrioli, R.; Sabbioni, C. and Pucci, V. (2004) Curr. Med. Chem., 11, 279-296.
8. Sandon, N.B.; Armstrong, S.C. and Cozza, K.L. (2005) Psychosomatics, 46, 464-494.
9. Krishna, D.R. and Klotz, U. (1994) Clin. Pharmacokinet., 26, 144-160.
10. Lin, J.H. and Lu, A.Y.H. (1998) Clin. Pharmacokinet., 35, 361-390.
11. Shen, W.W. (1997) Biol. Psychiatry, 41, 814-826.
12. Cozza, K.L.; Armstrong, S.C. and Oesterheld, J.R. (2003) Concise Guide to Drug Interactions Principles for Medical Practice, second edition, American Psychiatirc Publishing Inc., Washington, DC.
13. Shen, W.W. (1999) Ann. Clin. Psychiatry, 11, 145-158.
14. Aichhorn, W.; Whitworth, A.B.; Weiss, E.M.; and Marksteiner, J. (2006) Drug Safety, 29, 587-598.
15. Prior, T.I. and Baker, G.B. (2003) J. Psychiatr. Neurosci., 28, 99-112.
16. Spina, E. and de Leon, J. (2007) Basic Clin. Pharmacol. Toxicol., 100, 4-22.
17. Spina, E.; Scordo, M.G. and D'Arrigo, C. (2003) Fundam. Clin. Pharmacol., 17, 517-538.
18. Wright, S.A. and Ring, B.J. (1999) Drug Metab. Rev., 31, 15-28.
19. Byerly, M.J. and DeVane, C.L. (1996) J. Clin. Psychopharmacol., 16, 177-187.
20. Taylor, D. (1997) Br. J. Psychiatry, 171, 109-112.
21. Conley, R.R. and Kelly, D.L. (2007) Psychopharmacol. Bull., 40, 77-97.
22. DeVane, C.L. and Markowitz, J.S. (2000) Metabolic Drug Interactions, (Levy, R.H.; Thummel, K.E., Trager, W.F., Hansten, P.D. and Eichelbaum, M., Eds), Lippincott Williams & Wilkin; Philadelphia, PA, pp 245-257.
23. Pirmohamed, M.; Williams, D.; Madden, S.; Templeton, E. and Park, B.K. (1995) J. Pharmacol. Exp. Ther., 272, 984-990.
24. Eiermann, B.; Engel, G.; Johansson, I.; Zanger, U.M. and Bertilsson, L. (1997) Br. J. Clin. Pharmacol., 44, 439-446.
25. Linnet, K. and Olesen, O.V. (1997) Drug Metab. Dispos., 25, 1379-1382.
26. Olesen, O.V. and Linnet, K. (2001) J. Clin. Pharmacol., 41, 823-832.
27. Fang, J.; Coutts, R.T.; McKenna, K.F. and Baker, G.B. (1998) Naunyn-Schmiedeberg's Arch. Pharmacol., 358, 592-599.
28. Tugnait, M.; Hawes, E.M.; McKay, G.; Eichelbaum, M. and Midha K. (1999) Chem. Biol. Interact., 118, 171-189.
29. Vanier, J.L. and Chouinard, G. (1994) J. Clin. Psychopharmacol., 14, 284-285.
30. Odom-White, J.A. and de Leon, J. (1996) J. Clin. Psychiatry, 57, 175-176.
31. Carrillo, J.A.; Herraiz, A.G.; Ramos S.I. and Benitez M.D. (1998) J. Clin. Psychopharmacol., 18, 311-316.
32. Desai H.; Seabolt J. and Jann M.W. (2000) CNS Drugs, 15:469-494.
33. Haring, C.; Meise, U.; Humpel, C.; Saria, A.; Fleischacker, W.W. and Hinterhuber, H. (1989) Psychopharmacology (Berl), 99(Suppl), S38-S40.
34. Wetzel, H.; Anghelescu, L; Szegedi, A.; Wiesner, J.; Weigmann, H.; Hartter, S. and Hiemke, C. (1998) J. Clin. Psychopharmacol., 18, 2-9.
35. Seppälä, N.H.; Leinonen, E.V.J.; Lehtonen, M.L. and Kivistö, K.T. (1999) Pharmacol. Toxicol., 85, 244-246.
36. Hasegawa, M.; Gutierrez-Esteinou, R.; Way, L. and Meltzer, H.Y. (1993) J. Clin. Psychopharmacol., 13, 383-390.
37. McCarthy, R. (1994) Pharmacopsychiatry, 27, 210-211.
38. Skogh, E.; Bengtsson, F. and Nordin, C. (1999) Ther. Drug Monit., 21, 580-582.
39. Jeppessen, U.; Gram, L.F.; Vistisen, K.; Loft, S.; Poulsen, H.E. and Brosen, K. (1996) Eur. J. Clin. Pharmacol., 51, 73-78.
40. Jeppesen, U.; Rasmussen, B.B. and Brøsen, K. (1997) Clin. Pharmacol. Ther., 62, 279-286.
41. Chang, W.H.; Augustin, B.; Lane, H.Y.; ZumBrunnen, T.; Liu, H.C.; Kazmi, Y. and Jann, M. (1999) Psychopharmacol., 145, 91-98.
42. Olesen, O.V. and Linnet, K. (2000) J. Clin. Psychopharmacol., 20, 35-42.
43. Weigmann, H.; Muller, H.; Dahmer, W.; Wetzel, H. and Hiemke, C. (1993) Pharmacopsychiatry, 26, 209.
44. Hiemke, C.; Weigmann, H.; Härtter, S.; Dahmen, N.; Wetzel, H. and Muller, H. (1994) J. Clin. Psychopharmacol., 14, 279-281.
45. Jerling, M.; Lindström, L.; Bondesson, U. and Bertilsson, L.F. (1994) Ther. Drug Monit., 16, 368-374.
46. Szegedi, A.; Weisner, J. and Hiemke, C. (1995) J. Clin. Psychopharmacol., 15, 141-143.
47. Dequardo, J.R. and Roberts, M. (1996) Am J. Psychiatry, 153, 840-941.
48. DeMortier, G.; Lochu, A.; Colen, P.; Ghribi, O.; Roche-Rabreau, D.; DeGrassat, K. and Desce, J.M. (1996) Am. J. Psychiatry, 153, 738-739.
49. Koponen, H.J.; Leinonen, E. and Lepola, U. (1996) Eur. Neuropsychopharmacol., 6, 69-71.
50. Armstrong, S.C. and Stephans, J.R. (1997) J. Clin. Psychiatry, 58, 499.
51. Heeringa, M.; Beurskens, R.; Schouten, W. and Verduijn, M.M. (1999) Pharm. World Sci., 21, 243-244.
52. Lammers, C.H.; Deuschle, M.; Weigmann, H.; Härtter, S.; Hiemke, C.; Heese, C.; and Heuser, I. (1999) Pharmacopsychiatry, 32, 76-77.
53. Lu. M.L.; Lane, H.Y.; Chen, K.P.; Jann, M.W.; Su, M.H. Bind Chang, W.H. (2000) J. Clin. Psychiatry, 61, 594-599.
54. Joos, A.A.B.; Frank, U.G. and Kaschka, W.P. (1998) J. Clin. Psychopharmacol., 18, 83-85.
55. Wietholtz, H.; Zysset, T.; Marscha H.U.; Generet, K. and Matern, S. (1995)J. Hepatol., 22, 78-81.
56. Baciewicz, A.M. and Self, T.H. (1985) South Med. J., 78, 714-718.
57. Batty, K.Y.; Davis, T.M.; Ilett, K.F.; Dusci, L.J. and Langton, S.R. (1995) Br. J. Clin. Pharmacol., 39, 305-311.
58. Fuhr, U.; Anders, E.M.; Mahr, G.; Sorgel, F. and Staib, A.H. (1992) Antimicrob. Agents Chemother., 36, 942-948.
59. Markowitz, J.S.; Gill, H.S.; Devane, C.L. and Mintzer, J.E. (1997) Am. J. Psychiatry, 54, 881.
60. Raaska, K. and Neuvonen, P.J. (2000) Eur. J. Clin. Pharmacol., 56, 585-589.
61. Eggert, A-C.; Crismon, M.L. and Dovjon, P.G. (1994) J. Clin. Psychiatry, 55, 454-455.
62. Joos, A.A.B.; König, F.; Frank, U.G.; Kaschka, W.P.; Mörike, K.E. and Ewald, R. (1997) Pharmacopsychiatry, 30, 266-270.
63. Centorrino, F.; Baldessarini, R.J.; Frankenburg, F.R.; Kando, J.; Volpicelli, S.A. and Flood, J.G. (1996) Am. J. Psychiatry, 153, 820-872.
64. Centorrino, F.; Baldessarini, R.J.; Kando, J.; Frankenburg, F.; Volpicelli, S.A.; Puopolo, P.R. and Flood, J.G. (1994) Am. J. Psychiatty, 151, 123-125.
65. Spina, E.; Avenoso, A.; Facciolà G.; Fabraz o, M.; Mateleone, P.; Maj, M.; Perucca, E. and Caputi, A. (1998) Int. Clin. Psychopharmacol., 13, 141-145.
66. Tyson, S.C.; Devane, C.L. and Risch, S.C. (1995) Am. J. Psychiatry, 152, 1401-1402.
67. Koreen, A.R.; Lieberman, J.A.; Kronig, M. and Cooper, T.B. (1995) Am. J. Psychiatry, 152, 1690.
68. Dahl, M.L.; Llerena, A.; Bondesson, U.; Lindström, L. and Bertilsson, L. (1994) Br. J. Pharmacol., 37, 71-74.
69. Arranz, M.J.; Dawson, E.; Shaikh, S.; Sham, P.; Sharma, T.; Aritchison, K.; Kerwin, M.R. and Collier, D.A. (1995) Br. J. Clin Pharmacol., 39, 417-420.
70. Murray, M. (1992) Clin. Pharmacokinet., 23, 132-146.
71. Funderburg, L.; Vertrees, J.; True, J. and Miller, A. (1994) Am. J. Psychiatry, 151, 1840-1841.
72. Cohen; L.G.; Chesley, S.; Eugenio, L.; Flood, J.G.; Fisch, J. and Goff, D.C. (1996)Arch. Intern. Med., 156, 675-677.
73. Hägg, S.; Spigset, O.; Mjorndal, T.; Granberg, K.; Persbo-Lundqvist, G. and Dahlqvist, R. (1999) Eur. J. Clin. Pharmacol., 55, 221-226.
74. von Moltke, L.L.; Greenblatt, D.J.; Granda, B.W.; Grassi, J.M.; Schmider, J.; Harmatz, J.S. and Shader, R.I. (1999) Psychopharmacologia, 145, 113-122.
75. Khan, A.Y. and Preskorn, S.H. (2001) J. Clin. Psychiatry, 62, 375-376.
76. Taylor, D.; Bodani, M.; Hubbeling, A. and Murray, R. (1999) Int. Clin. Psychopharmacol., 14, 185-187.
77. Raaska, K. and Neuvonen, P.J. (1998) Eur. J. Clin. Pharmacol., 54, 167-170.
78. Ring, B.J.; Binkley, S.N.; Vandenbranden, M. and Wrighton, S.A. (1996) Br. J. Clin. Pharmacol., 41, 181-186.
79. Shin, J.G.; Soukhova, N. and Flockhast, D.A (1999) Drug Metab. Dispos., 27, 1078-1084.
80. Smith, T. and Risken, J. (1994) Pharmacopsychiatry, 27, 41-42.
81. Caccia, S. (2000) Clin. Pharmacokinet., 38, 393-414.
82. Lavrijsen, K.; Meuldermans, W. and Heykants, J. (1993) Janssen Preclinical Research Report R64 776/FK1257. Bruges, Belgium. Janssen.
83. Fang, J.; Bourin, M. and Baker, G.B. (1999) Naunyn-Schmiedebergs Arch. Pharmacol., 359 147-151.
84. Mannens, G.; Huang, M.L.; Meuldermanns, W.; Hendricks, J.; Woestenborghs, R. and Heykants, J. (1993) Drug Metab. Dispos., 21, 1134-1141.
85. Huang, M.L.; van Peer, A.; Woestenborghs, R.; DeCoster, R.; Heykants, J.; Jansen, A.A.J., Zylic, Z.; Visscher, H.W. and Jorkmann, J.H. (1993) Clin. Pharmacol. Ther., 54, 257-268.
86. Berecz, R.; Llerena, A.; de la Rubia, A.; Gomez, J.; Kellerman, M.; Dorado, P., and Degrell, I. (2002) Pharmacopsychiatry, 35, 231-234.
87. Olesen, O.V.; Licht, R.W.; Thomsen, E.; Bruun, T.; Viftrup, J.E. and Linnet, K. (1998) Ther. Drug Monit., 20, 380-384.
88. Scordo, M.G.; Spina, E.; Facciolà, G.; Avenoso, A.; Johansson, I. and Dahl, M.L. (1999) Psychopharmacology, 147, 300-305.
89. Bork, J.A.; Rogers, T.; Wedlund, P.J. and de Leon, J. (1999) J. Clin. Psychiatry, 60, 469-476.
90. Spina, E.; Avenoso, A.; Facciolà, G.; Scordo, M.G.; Ancione, M. and Madia, A. (2001) Ther. Drug Monit., 23, 223-237.
91. Spina, E.; Avenso, A.; Scordo, M.G.; Ancione, M.; Madia, A.; Gatti, G.; and Percucca, P. (2002) J. Clin. Psychopharmacol., 22, 419-442.
92. Nakagami, T.; Yasui-Furukori, N.; Saito, M.; Mihara, K.; De Vries, R.; Kondo, T. and Kaneko, S. (2005) J. Clin. Psychopharmacol., 25(1), 89-91.
93. Snoeck, E.; Van Peer, A.; Sack, M.; Horton, M.; Mannens, G.; Woestenborghs, R.; Heykants, J. and Metach, R. (1995) Psychopharmacology, 122, 223-229.
94. Knegtering, R.; Baselmans, P.; Castelein, S.; Bosker, F.; Bruggeman, R.; and van den Bosch, R.J. (2005) Am. J. Psychiatry, 162, 1010-1012.
95. Leonard, B.E. (2001) Psychopharmacol., 16, S79-S84.
96. Baker, G.B. and Prior, T.I. (2002) Ann. Med., 34, 537-43.
97. Yasui-Furukori, N.; Hidestrand, M.; Spina, E. and Faccioli, G. (2001) Drug Metab. Dispos., 29, 1263-1268.
98. De Leon, J. and Bork, J. (1997) J. Clin. Psychiatry, 58, 10.
99. Spina, E.; Scordo, M.G.; Avenoso, A. and Perucca, E. (2001) J. Clin. Psychopharmacol., 21, 108-109.
100. DeVane, C.L. and Nemeroff, C.B. (2001) J. Clin. Psychopharmacol., 21, 408-416.
101. Llerena, A.; Berecz, R.; Dorado, P.; and de la Rubia, A. (2004) J. Psychopharmacol., 18, 189-193.
102. Boulton, D. W.; DeVane, C. L.; Liston, H. L. and Markowitz, J. S. (2002) Life Sci., 71, 163-169.
103. Doran, A.; Obach, R.S.; Smith, B.J.; Hosea, N.A.; Becker, S.; Callegari, E.; Liu, X.; Chen, C.; Chen, X.; Ciafrogna, J.; Doran, S.; Liu, J.; Nelson, F.; Szewc, M. and van Deusen, J. (2005) Drug Metab. Dispos., 33, 165-174.
104. Wang, J.S.; Ruan, Y.; Taylor, R.M.; Donovan, J.L.; Markowitz, J.S. and DeVane, C.L. (2004) Int. J. Neuropsychopharmacol., 7, 415-419.
105. Wang, J.S.; Zhu, H.J.; Markowitz, J.S.; Donovan, J.L. and DeVane, C.L. (2006) Psychopharmacol., 187(4), 415-423.
106. Zhu, H.J.; Wang, J.S.; Markowitz, J.S.; Donovan, J.L.; Gibson, B.B. and DeVane, C.L. (2007) Neuropsychopharmacology, 32, 757-764.
107. Ejsing, T.B.; Pedersen, A.D. and Linnet, K. (2005) Human Psychopharmacol., 20, 493-500.
108. Markowitz, J.S.; Devane, C.L.; Liston, H.L.; Boulton, D.W. and Risch, SC. (2002) Clin. Pharmacol. Ther., 71; 30-38.
109. Ring, B.J.; Catlow, J.; Lindsay, T.J.; Gillespie, T.; Roskos, L.K.; Cerimele, B.J., et al. (1996) J. Pharmacol. Exp. Ther., 276, 658-666.
110. Callaghan, J.T.; Bergstrom, R.F.; Ptak, L.R. and Beasley, C.M. (1999) Clin. Pharmacokinet., 37, 177-193.
111. Mäenpää, J.; Wrighton, S.; Bergstrom, R.; Cerimele, B.; Tatum, D.; Hatcher, B., et al. (1997) Clin. Pharmacol. Ther., 61, 225.
112. Markowitz, J.S. and DeVane, C.L. (1999) J. Clin. Psychopharmacol., 19, 289-291.
113. Parker, A.C.; Pritchard, P.; Preston, T. and Choonara, I. (1998) Br. J. Clin. Pharmacol., 45; 176-178.
114. Lucas, R.A.; Gilfillan, D.J. and Bergstrom,. R.F. (1998) Eur. J. Clin. Pharmacol., 54, 639-643.
115. Olesen, O.V. and Linnet, K. (1999) Ther. Drug Metab., 21, 87-90.
116. Macias, W.L.; Bergstrom, R.F.; Cerimele, B.J.; Kassahm, K.; Tatum, D.E. and Callaghan, J.T. (1998) Pharmacotherapy, 18, 1237-1248.
117. Dev, V. and Raniwalla, J. (2000) Drug Safety, 23, 296-307.
118. Goldstein, J.M. (1999) Drugs Today, 35, 193-210.
119. Savasi, I.; Millson, R.C. and Owen, J.A. (2002) Can. J. Psychiatry, 47, 94.
120. Wong, Y.W.J.; Yeh, C. and Thyrum, P.T. (2001) J. Clin. Psychopharmacol., 21, 89-93.
121. Miceli, J.J.; Smith, M.; Robarge, L.; Morse, T. and Laurant, A. (2000) Br. J. Clin. Pharmacol., 49, 715-765.
122. Calabrese, J.R.; Keck, P.E. Jr.; Macfadden, W.; Minkwitz, M.; Ketter, T.A.; Weisler, R.H.; Cutler, A.J.; McCoy, R.; Wilson, E. and Mullen, J. (2005) Am. J. Psychiatry, 162, 1351-1360.
123. Thase, M.E.; Macfadden, W.; Weisler, R.H.; Chang, W.; Paulsson, B.; Khan, A. and Calabrese, J.R.. for the BOLDER II Study Group (2006) J. Clin. Psychopharmacol., 26, 600-609.
124. Goldstein, J.M.; Christoph, G.; Grimm, S.; Liu, J.W.; Widzowski, D. and Brecher, M. (2007). Proceeding of 62nd Annual Meeting Society Biological Psychiatry, May 17-19, San Diego, CA, USA.
125. Beedham, C.; Miceli, J.J. and Obach, R.S. (2003) J. Clin. Psychopharmacol., 23, 229-232
126. Wilner, K.D.; Demattos, S.B.; Anziano, R.J.; Apseloff, G. and Gerber, N. (2000) Br. J. Clin. Pharmacol., 49, (Suppl. 1) 43S-47S.
127. Prakash, C.; Kamel, A.; Cui, D.; Whalen, R.D.; Miceli, J.J. and Tweedie, D. (2000) Br. J. Clin. Pharmacol., 49 (Suppl 1), 35S-421.
128. Miceli, J.J.; Wilner, K.D.: Hansen, R.A.; Johnson, A.C.; Abelsoff, G. and Gerber, L. (2000) Br J Clin Pharmacol., 49(Suppl), 5-13.
129. Miceli, J.J.; Smith, M.; Robarge, L.; Morse, T. and Laurent, A. (2000) Br. J. Clin. Pharmacol., 49, (Suppl. 1) 71S-76S.
130. Wilner, K.D.; Hansen, R.A.; Folger, C.J. and Geoffroy, P. (2000) Br. J. Clin. Pharmacol., 49 (Suppl 1) 57S-60S.
131. Miceli, J.J.; Anziano, R.J., Robarge, L., Hansen, R.A. and Laurent, A. (2000) Br. J. Clin. Pharmacol., 49(Suppl 1), 65S-70S.
132. Gunasekara, N.S., Spencer, C.M. and Keating, G.M. (2002) Drugs, 62, 1217-1251.
133. Preskorn, S. (2005) Clin. Pharmacokinet., 44, 1117-1133.
134. Swainston Harrison, T. and Scott, L.J. (2006) CNS Drugs, 20, 1027-1052.
135. Apseloff, G.; Mullet, D.; Wilner, K.D.; Anziano, R.J.; Tensfeldt, T.G.; Pelletier, S.M. and Gerber, N. (2000) Br. J. Clin. Pharmacol., 49(Suppl 1); 61S-64S.
136. DeLeon, A.; Patel, N.C. and Crismon, M.L. Aripiprazole; (2004) Clin Ther., 26 (5), 649-666.
137. Molden, E.; Lunde, N.; Lunder, H. and Refsum, H. (2006) Ther. Drug Monit., 28, 744-749.
138. Gupta, S. and Masand, P. (2004) Ann. Clin. Psychiatry, 16, 155-166.
139. Abilify (aripiprazole) [package insert]. Available at www.abilify.com.
140. Kubo, M.; Koue, T.; Inaba, A.; Takeda, H.; Maune, H.; Fukuda, T. and Azuma, J. (2005) Drug Metab. Pharmacokinet., 20, 55-64.
141. Invega (paliperidone) package insert (2007) Titusville, N.J. Janssen Pharma.
142. Dolder, C.; Nelson, M. and Deyo, Z. (2008) Am. J. Health Syst., Pharm., 65, 434-441.
143. Rosenzweig, P.; Canal, M.; Patat, A.; Bergougnan, L.; Zieleniuk, I. and Bianchetti, G. (2002) Hum Psychopharmacol., 17, 1-13.
144. Bergemann, N.; Kopitz, J.; Kress, K.R. and Frick, A. (2004) Eur. Neuropsychopharmacol., 14, 245-250.
145. Gillet G.; Domerque, L.; Canal, M. and Thenot, J.P., (2000) Eur. Neuropsychopharmacol., 10(Suppl 3), 331-332.